Recent Quotes (30 days)

You have no recent quotes
chg | %

Neurokine Pharmaceuticals Inc  

(Public, OTCMKTS:NEUKF)   Watch this stock  
Find more results for OTC:NEUKF
0.00000 (0.00%)
Mar 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.04
Open     -
Vol / Avg. 0.00/9,703.00
Mkt cap 1.04M
P/E     -
Div/yield     -
EPS 0.00
Shares 115.77M
Beta -12.54
Inst. own     -

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -6931.72% -
Return on average equity - -
CDP Score - -


1275 6th Ave W
+1-604-8057783 (Phone)
+1-604-2250588 (Fax)

Website links


Neurokine Pharmaceuticals Inc. is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. Its research and development activities are focused on assessing known drugs and compounds, developing hypotheses concerning their usage for new indications (diseases), and conducting experimentation and clinical research to test those hypotheses. As of January 31, 2014, the Company had identified two anti-inflammatory products, which included NK-001 and NK-002. NK-001 holds prospect for the treatment of neurocognitive impairment. NK-002 holds prospect for treatment of Alzheimer�s disease. Both of the Company�s planned products are in the development stage.